Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Seliciclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 known ✓ | P06493 | 14/20 | 1.00 |
| ▸ | CDK5 known ✓ | Q00535 | 10/20 | 1.00 |
| ▸ | CDK2 known ✓ | P24941 | 9/20 | 1.00 |
| ▸ | CDK7 known ✓ | P50613 | 6/20 | 1.00 |
| ▸ | CDK9 known ✓ | P50750 | 5/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 7/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 6/20 | 1.00 |
| ▸ | CCNK | O75909 | 6/20 | 1.00 |
| ▸ | CDK12 | Q9NYV4 | 6/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 4/20 | 1.00 |
| ▸ | CDK4 | P11802 | 4/20 | 1.00 |
| ▸ | CCND1 | P24385 | 4/20 | 1.00 |
| ▸ | CCNH | P51946 | 4/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 3/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 3/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 2/20 | 1.00 |
| ▸ | CLK2 | P49760 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (Rs)-Roscovitine SCHEMBL172593 | 1.00 | CDK1 (1.00) | CDK1CDK5CDK2CCNE1CDK7 | |
| (S)-Roscovitine SCHEMBL29415376 | 1.00 | CDK1 (1.00) | CDK1CDK5CDK2CCNE1CDK7 | |
| (S)-Roscovitine SCHEMBL2907488 | 1.00 | CDK1 (1.00) | CDK1CDK5CDK2CCNE1CDK7 | |
| (Rs)-Roscovitine SCHEMBL15163619 | 1.00 | CDK1 (1.00) | CDK1CDK5CDK2CCNE1CDK7 | |
| SCHEMBL17628573 | 0.94 | CDK2 (1.00) | CDK1CDK5CDK2CCNE1CDK7 | |
| SCHEMBL13001898 | 0.94 | CDK2 (1.00) | CDK1CDK5CDK2CCNE1CDK7 | |
| SCHEMBL14403894 | 0.94 | CDK1 (0.88) | CDK1CDK5CDK2CCNE1CDK7 | |
| SCHEMBL1213597 | 0.92 | CDK1 (1.00) | CDK1CDK5CDK2CCNE1CDK7 | |
| SCHEMBL2098199 | 0.92 | CDK1 (1.00) | CDK1CDK5CDK2CCNE1CDK7 | |
| SCHEMBL23198590 | 0.92 | CDK1 (0.85) | CDK1CDK5CDK2CCNE1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4085 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| WO-2025217307-A9 | METHODS FOR PREDICTING RESPONSE TO A RAS(ON) INHIBITOR AND COMBINATION THERAPIES | Revolution Medicines, Inc. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| US-20260076952-A1 | Agent for Treatment of Neutropenia | UNIV TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2026-03-19 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-12558308-B2 | Drug-loaded biodegradable microbead compositions including drug-containing vesicular agents | C.R. BARD, INC. (US) | 2026-02-24 | — | — | US | claimed |
| EP-4695235-A1 | NOVEL GSPT1 DEGRADER AND USE THEREOF | Cyrus Therapeutics Inc. (KR) | 2026-02-18 | — | — | EP | claimed |
| EP-2562265-A1 | Susceptibility to selective CDK9 inhibitors | Lead Discovery Center GmbH (DE) | 2013-02-27 | — | — | EP | claimed |
| EP-2561867-A1 | CDK9 inhibitors in the treatment of midline carcinoma | Lead Discovery Center GmbH (DE) | 2013-02-27 | — | — | EP | claimed |
| US-20070275986-A1 | Use of purine derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2007-11-29 | — | — | US | claimed |
| EP-1841401-A1 | REDUCTION OF HAIR GROWTH WITH SURVIVIN INHIBITORS | The Gillette Company (US) | 2007-10-10 | — | — | EP | claimed |
| WO-2006069192-A1 | REDUCTION OF HAIR GROWTH WITH SURVIVIN INHIBITORS | THE GILLETTE COMPANY (US) | 2006-06-29 | — | — | WO | claimed |
| US-20060135461-A1 | Reduction of hair growth | GILLETTE COMPANY, THE | 2006-06-22 | — | — | US | claimed |
| US-20030186999-A1 | Purine derivatives having, in particular, antiproliferative properties, and their biological uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIGUE (C.N.R.S.) | 2003-10-02 | — | — | US | claimed |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | claimed |
| EP-0874847-B1 | NOVEL PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTIPROLIFERATIVE PROPERTIES, AND BIOLOGICAL USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2003-03-19 | — | — | EP | claimed |
| US-20020049218-A1 | Purine derivatives having, in particular, antiproliferative properties, and their biological uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIGUE (C.N.R.S.) | 2002-04-25 | — | — | US | claimed |